Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Nasacort 55 micrograms/dose, nasal spray, suspension
⚠ This medicine appears to have been discontinued
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Triamcinolone acetonide may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
What it is and what it is used for
for 2. What you need to know before you use Nasacort 3. How to use Nasacort 4. Possible side effects 5. How to store Nasacort 6. Contents of the pack and other information
Animal fur or house dust mites. This type of allergy can happen at any time of the year and is called 'perennial allergic rhinitis'. Pollen. This type of allergy, such as hay fever, can be caused by different pollens in different seasons of the year. This is called 'seasonal allergic rhinitis'. This medicine only works if used on a regular basis and may not help your symptoms straight away. It helps some people within the first day of treatment, however, for other people it may take 3 to 4 days to feel a relief.
What you need to know before you take it
e Nasacort Do not use Nasacort: If you are allergic to triamcinolone acetonide or any of the other ingredients of this medicine (listed in section 6) Signs of an allergic reaction to Nasacort include: a rash (hives), itching, swallowing or breathing problems, swelling of your lips, face, throat or tongue. Warning and precautions Talk to your doctor or pharmacist before using Nasacort: If you have any infection of the nose or throat that is not treated. If you get a fungal infection while using Nasacort, stop using the spray until the infection has been treated. If you have recently had a nose operation, or had an injury or ulcer in the nose. If you are being transferred from steroid injections or tablets to Nasacort spray. If you have had glaucoma or cataracts If you are not sure if any of the above apply to you, talk to your doctor or pharmacist
Children (under 2 years) This medicine is not recommended for use in children under 2 years of age.
Other medicines and Nasacort Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription. This is because Nasacort can affect the way some other medicines work. Also some medicines can affect the way Nasacort works. Some medicines may increase the effects of Nasacort and your doctor may wish to monitor you carefully if you are taking these medicines (including some medicines for HIV: ritonavir, cobicistat). Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Driving and using machines Nasacort has no or negligible influence on the ability to drive or use machines. Nasacort contains benzalkonium chloride This medicine contains 15 micrograms benzalkonium chloride in each spray. Benzalkonium chloride may cause irritation or swelling inside the nose, especially if used for a long time.
Systemic effects When corticosteroids, including triamcinolone acetonide, are used for long periods of time or at high doses for long periods of time, side effects may occur due to the drug being absorbed in the body (e.g. the normal production of steroidal hormones may be affected). These side effects are much less likely to occur with corticosteroid nasal sprays than with corticosteroids taken orally (e.g. tablets). Talk to your doctor if you experience any side effects. 3. How to use Nasacort NASACORT is for nasal use only. Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. The medicine only works if it is used regularly. It can take 3 to 4 days before you notice your symptoms getting better. How much Nasacort to use Adults and children (over 12 years) The usual starting dose is 2 sprays in each nostril each day Once the symptoms of allergy are under control, the dose may be lowered to 1 spray in each nostril each day Children (6 to 12 years) The usual dose is 1 spray in each nostril each day If the symptoms do not go away, then the dose may be increased to 2 sprays in each nostril each day The dose can then be lowered again to 1 spray in each nostril each day Children (2 to 5 years) The usual dose is 1 spray in each nostril each day Do not use Nasacort for more than 3 months in children under 12 years old. An adult should help a young child use this medicine.
How to take it
the spray Before using your nasal spray, blow your nose gently to clear your nostrils.
1. Preparing the bottle 1 Remove the cap by pulling upward Shake the bottle gently before use 2. If you are using the spray for the first time Hold the bottle upright Point the spray away from you while doing this Fill the pump with spray by pressing the nozzle downwards. This is called priming 2 Press and release it 5 times Do this until a fine spray is produced The spray is now ready to use 3. Using the spray Close one nostril with your finger Hold the bottle upright and put the nozzle into the other nostril as far as is comfortable 3 Breathe in gently through your nose with your mouth closed While you are doing this, press the nozzle to deliver one spray 4. Then breath out through your mouth 5. Repeat steps 3 and 4 if you have to spray again in the same nostril and for the other nostril Correct Position 6. After using the spray To keep the spray nozzle clean, wipe it carefully with a clean 3 tissue or handkerchief after each use Replace the cap over the nozzle If the nasal spray has not been used for more than 2 weeks: It needs to be primed again, to fill the nozzle with the spray The nozzle should be pointed away from you while you are doing this To prime, spray into the air once before use Always shake the bottle gently before use
Wrong Position
Turn Over
File information GMID code:
723777
Plant PM code:
R01765
Second Plant PM code: R01765 Version of artwork:
V1
PM type:
PI
Market:
GB
Format:
625 x 150 mm
Free area
Lacquer-free
Technical information a = Batch No.
b = Expiry date
c = Manufacturing date
d = Price/Sample/Cinic
Braille
UK
MINIMUM POINT SIZE
10
COLOURS USED
COMP. CODE
R01765
cutter
R01544 1
15/Jul/2025
Print colors:
Black
PROOF NO.
Used font:
Ocean Sans
Min. font size:
10 pt
VDR size:
X pt
16.5g
226147
Issue date of artwork:
Number of print colors: 1
FILL WEIGHT
JOB NUMBER
BASED ON
Technical colors Diecut-Legendcase
COUNTRY
CPRO
1-53
SIZE (mm)
625 x 150
1895
Print free area 15/Jul/2025
Black
THIS ARTWORK PROOF INDICATES COLOUR POSITION ONLY
Please refer to Pantone Colour Formula Guide 1000 for exact colour references
Cleaning the spray If the spray does not work, the nozzle may be blocked. Never try to unblock it or enlarge the tiny spray hole with a pin or other sharp objects. This is because it can stop the spray from working.
If you stop using Nasacort If you stop using this medicine, your symptoms may return within a few days. If you experience any side effects (withdrawal symptoms) after stopping this medicine suddenly after prolonged use, talk to your doctor. See section 4 'Possible side effects' for more information.
The nasal spray should be cleaned at least once a week. It can be cleaned more often if it gets blocked. Instructions for cleaning the spray: 1. Remove the cap 2. Gently pull off the spray nozzle only
Spray Nozzle
Bottle Cap Bottle
3. Soak the cap and spray nozzle in warm water for a few minutes 4. Rinse under the cold running tap water 5. Shake or tap to remove any water that is left 6. Allow to dry in the air 7. Re-fit the spray nozzle 8. Prime the nasal spray until a fine mist is formed 9. Use as normal If you use more Nasacort than you should It is important that you take your dose as stated on the pharmacist's label or as advised by your doctor. You should use only as much as your doctor recommends; using more or less may make your symptoms worse.
Like all medicines, this medicine can cause side effects, although not everybody gets them. Stop using Nasacort and see a doctor or go to a hospital straight away if: You have an allergic reaction to Nasacort. The signs (frequency not known) may include: a rash (hives), itching, swallowing or breathing problems, swelling of your lips, face, throat or tongue. Common side effects (may affect up to 1 in 10 people) Runny nose, headache, sore throat and/or cough Nosebleeds Inflammation/irritation of the airways (bronchitis) Heartburn or indigestion Flu-like symptoms (fever, muscle pain, weakness and/or fatigue) Problems with teeth Other side effects (Not known: frequency cannot be estimated from the available data) Irritation and dryness on the inside of your nose Sinuses become congested or blocked Sneezing Changes in the way things taste or smell Feeling sick (nausea) Sleeping problems, feeling dizzy or tired
In some people, Nasacort can cause damage to the middle part of the inside of the nose (called 'nasal septum'). Discuss any worries you may have about this with your doctor or pharmacist. Additional side effects in Children If your child has been using this medicine, it can affect how fast your child grows. This means that your doctor will need to regularly check your child's height and therefore your doctor may lower the dose. In addition, your doctor may consider referring your child to a paediatric specialist. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Possible side effects
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
This leaflet was last revised in 07/2025
NASACORT AQ
An overdose is unlikely to cause problems, however, if you have taken the entire contents of the bottle by mouth you may have stomach or gut discomfort. Talk to a doctor if you use more Nasacort than you should.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Shortness of breath (dyspnoea) A decrease in the levels of cortisol in the blood (lab value) Cloudiness of the lens in the eye (cataract), elevated pressure inside the eyeball (glaucoma) Blurred vision Sudden discontinuation of corticosteroids after prolonged use may result in withdrawal symptoms like joint pain, muscle pain, shaking, weight loss, anxiety, nasal drip and bleeding from the nose. However, these symptoms are extremely rare for corticosteroid nasal sprays, and much less likely to occur with corticosteroid nasal sprays than with corticosteroids taken orally (e.g. tablets).
How to store it
Nasacort Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and the bottle after "EXP". The expiry date refers to the last day of that month. Do not store above 25°C. Following the first opening Nasacort should be used within 1 month for the 30 spray pack or 2 months for the 120 spray pack.
Contents of the pack and other information
What Nasacort contains The active substance is triamcinolone acetonide. One delivered dose contains 55 micrograms of triamcinolone acetonide. The other ingredients are: Spray Nozzle
- microcrystalline cellulose and carmellose sodium (dispersible cellulose)
- polysorbate 80 Bottle
- purified water Bottle Cap
- anhydrous glucose
- benzalkonium chloride (50% w/v solution)
- disodium edetate
- hydrochloric acid or sodium hydroxide (for pH-adjustment) What Nasacort looks like and contents of the pack Nasacort is a nasal spray suspension. It comes in a white plastic bottle which has a pump to spray Nasacort into your nostril through the spray nozzle. The bottle has a protective cap to keep the nozzle clean and to stop it from spraying accidentally. This one spray bottle holds at least 120 sprays (16.5g of suspension which contains 9.075 mg triamcinolone acetonide) or at least 30 sprays (6.5g of suspension which contains 3.575 mg triamcinolone acetonide). Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder : Opella, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK. Tel: 0800 035 2525 email: [email protected]
Manufacturer : Bespak HC Limited, London Road, Holmes Chapel, Cheshire CW4 8BE, United Kingdom. Sanofi Winthrop Industrie, 30-36, avenue Gustave Eiffel, 37100 Tours, France. This medicinal product is authorised in the Member States of the EEA under the following names : Austria: Belgium: Bulgaria: Czech Republic: Denmark: Estonia: Finland: Germany: Greece: Hungary: Ireland: Italy: Latvia: Lithuania:
Nasacort Nasenspray Nasacort Nasacort Triamcinolone sanofi 55 mikrogramů/dávka Nasacort Nasacort Nasacort Nasacort 55 Mikrogramm/Dosis Nasacort Nasacort Nasacort nasal spray Nasacort Nasacort Triamcinolone acetonide Sanofi 55μg/dose nasal spray, suspension Luxembourg: Nasacort Netherlands Nasacort Poland: Nasacort Portugal: Nasacort Nasacort 55 micrograme/ Romania: doza spray nazal, suspensie Slovakia: Nasacort 55 mikrogramov/dávka Slovenia: Nasacort Spain: Nasacort Sweden: Nasacort United Kingdom: Nasacort nasal spray R01765
If you forget to use Nasacort If you have forgotten to use Nasacort, use it as soon as you remember. Do not use a double dose to make up for a forgotten dose.
Frequently asked questions about Nasacort 55 micrograms/dose, nasal spray, suspension
How do I take Nasacort 55 micrograms/dose, nasal spray, suspension?
Nasacort 55 micrograms/dose, nasal spray, suspension comes as oral solution containing 55mcg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
What is the active substance in Nasacort 55 micrograms/dose, nasal spray, suspension?
The active substance in Nasacort 55 micrograms/dose, nasal spray, suspension is triamcinolone acetonide.
Where does this information come from?
This leaflet reproduces the patient information leaflet approved for Nasacort 55 micrograms/dose, nasal spray, suspension, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Can I get Nasacort 55 micrograms/dose, nasal spray, suspension without a prescription?
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
About this leaflet
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
- Source: electronic medicines compendium (emc), Datapharm
- Active substance: triamcinolone acetonide
- Official document: view the original leaflet on emc →
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
4.1. Therapeutic indications
NASACORT is indicated for the treatment of symptoms of seasonal and perennial allergic rhinitis in adults and children 2 years of age and over.
4.2. Posology and method of administration
Posology
Adults:
The recommended starting dose is 220 micrograms as 2 sprays in each nostril once daily. Once symptoms are controlled patients can be maintained on 110 micrograms (1 spray in each nostril once daily).
Paediatric population
Children aged 12 years and over:
The recommended starting dose is 220 micrograms as 2 sprays in each nostril once daily. Once symptoms are controlled patients can be maintained on 110 micrograms (1 spray in each nostril once daily).
Children aged 6 to 12 years:
The recommended dose is 110 micrograms as 1 spray in each nostril once daily. In patients with more severe symptoms, a dose of 220 micrograms may be used. But once symptoms are controlled, patients should be maintained on the lowest effective dose. (see sections 4.4 and 5.1).
Children aged 2 to 5 years:
The recommended and maximum dose is 110 micrograms as 1 spray in each nostril once daily (see sections 4.4 and 5.1).
Continuous use beyond 3 months in children under 12 years is not recommended.
Method of administration
NASACORT is for nasal use only.
It is important to shake the bottle gently before each use.
Each actuation delivers 55 micrograms triamcinolone acetonide from the nose piece to the patient (estimated from in vitro testing) after an initial priming of 5 sprays until a fine mist is achieved. NASACORT will remain adequately primed for 2 weeks. If the product is unused for more than 2 weeks, then it can be adequately reprimed with one spray. The nozzle should be pointed away from you while you are doing this.
After using the spray: Wipe the nozzle carefully with a clean tissue or handkerchief, and replace the cap.
If the spray does not work and it may be blocked, clean it as follows. NEVER try to unblock it or enlarge the tiny spray hole with a pin or other sharp object because this will destroy the spray mechanism.
The nasal spray should be cleaned at least once a week or more often if it gets blocked.
TO CLEAN THE SPRAY
1. Remove the cap and the spray nozzle only* (pull off).
2. Soak the cap and spray nozzle in warm water for a few minutes, and then rinse under cold running tap water.
3. Shake or tap off the excess water and allow to air-dry.
4. Re-fit the spray nozzle.
5. Prime the unit as necessary until a fine mist is produced and use as normal.
* Part as indicated on diagram below,
Also, the bottle should be discarded after 30 actuations or within one month of starting treatment (6.5 g pack), or after 120 actuations or within 2 months of starting treatment (16.5 g pack). Do not transfer any remaining suspension to another bottle.
4.3. Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
4.4. Special warnings and precautions for use
If there is any reason to suppose that adrenal function is impaired, care must be taken while transferring patients from systemic steroid treatment to NASACORT.
In clinical studies with NASACORT administered intranasally, the development of localised infections of the nose and pharynx with Candida albicans has rarely occurred. When such an infection develops it may require treatment with appropriate local therapy and temporary discontinuation of treatment with NASACORT.
Because of the inhibitory effect of corticosteroids on wound healing in patients who have experienced recent nasal septal ulcers, nasal surgery or trauma, NASACORT should be used with caution until healing has occurred.
Systemic effects of nasal corticosteroids may occur, particularly when used for prolonged duration or at high doses prescribed for prolonged periods. These effects are much less likely to occur than with oral corticosteroids and may vary in individual patients and between different corticosteroid preparations (may vary as per the potency, dosage form and pharmacokinetic properties (lipophilicity, volume of distribution and elimination half-life) of the steroid). Potential systemic effects may include Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, cataract, glaucoma and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children).
Treatment with higher than recommended doses may result in clinically significant adrenal suppression. If there is evidence of using higher than recommended doses then additional systemic corticosteroid cover should be considered during periods of stress or elective surgery.
The risks associated with sudden discontinuation of corticosteroids after prolonged use may include exacerbation or recurrence of the underlying disease, adrenocortical insufficiency or steroid withdrawal syndrome. However, these effects are extremely rare for nasal corticosteroids, and much less likely to occur with nasal corticosteroids than with oral corticosteroids.
Glaucoma and/or cataracts have been reported in patients receiving nasal corticosteroids. Therefore, close monitoring is warranted in patients with a change in vision or with a history of increased intraocular pressure, glaucoma and/or cataracts.
Visual disturbance
Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.
NASACORT contains benzalkonium chloride, long term use may cause oedema of the nasal mucosa.
Paediatric population
NASACORT is not recommended for use in children under 2 years of age.
Reduction in growth velocity has been reported in children receiving nasal corticosteroids, including NASACORT at licensed doses. See section 5.1.
It is recommended that the height of children receiving treatment with nasal corticosteroids is regularly monitored. Therapy should be managed with the aim of reducing the dose of nasal corticosteroid, if possible, to the lowest dose at which effective control of symptoms is maintained. The long-term effects of reduction in growth velocity associated with nasal corticosteroids, including the impact on final adult height are unknown. In addition, consideration should be given to referring the patient to a paediatric specialist, especially for children under the age of 6 years this is strongly recommended.
4.5. Interaction with other medicinal products and other forms of interaction
Co-treatment with CYP3A inhibitors, including cobicistat-containing products, is expected to increase the risk of systemic side-effects. The combination should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid side-effects, in which case patients should be monitored for systemic corticosteroid side-effects.
4.6. Fertility, pregnancy and lactation
Clinical experience in pregnant women is limited. In animal studies, corticosteroids have been shown to induce teratogenic effects. Triamcinolone acetonide may pass into human breast milk. Triamcinolone acetonide should not be administered during pregnancy or lactation unless the therapeutic benefit to the mother is considered to outweigh the potential risk to the foetus/baby.
4.7. Effects on ability to drive and use machines
NASACORT has no or negligible influence on the ability to drive and use machines.
4.8. Undesirable effects
The adverse events reported in clinical trials with NASACORT most commonly involved the mucous membranes of the nose and throat.
The following terminologies have been used in order to classify the occurrence of adverse reactions:
Very common ≥1/10; Common ≥1/100 and <1/10; Uncommon ≥ 1/1,000 and < 1/100; Rare ≥ 1/10,000 and <1/1,000; Very rare < 1/10,000 and not known (cannot be estimated from the available data).
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness
The most frequent adverse reactions in adults and children 2 years of age and older were:
• Infections and infestations
Common: flu syndrome, pharyngitis, rhinitis
• Immune system disorders
Not known: hypersensitivity (including rash, urticaria, pruritus and facial oedema)
• Endocrine disorders
Not known: steroid withdrawal syndrome (see section 4.4)
• Psychiatric disorders
Not known: insomnia
• Nervous system disorders
Common: headache
Not known: dizziness, alterations of taste and smell
• Eye disorders
Not known: chorioretinopathy, cataract, glaucoma, increased ocular pressure, blurred vision (see also section 4.4).
• Respiratory, thoracic and mediastinal disorders
Common: bronchitis, epistaxis, cough
Rare: nasal septum perforations
Not known: nasal irritation, dry mucous membrane, nasal congestion, sneezing, dyspnoea
• Gastrointestinal disorders
Common: dyspepsia, tooth disorder
Not known: nausea
• General disorders and administration site conditions
Not known: fatigue
• Investigations
Not known: decreased blood cortisol
Reduction of growth velocity has been observed in children during a post-marketing clinical trial with NASACORT (see section 5.1)
Systemic effects of nasal corticosteroids may occur, particularly when prescribed at high doses for prolonged periods. Growth retardation has been reported in children receiving intranasal steroids.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
4.9. Overdose
Like any other nasally administered corticosteroid, acute overdosing with NASACORT is unlikely in view of the total amount of active ingredient present. In the event that the entire contents of the bottle were administered all at once, via either oral or nasal application, clinically significant systemic adverse events would most likely not result. The patient may experience some gastrointestinal upset if taken orally.
🇵🇱 Known in Poland as
Medicines sold in Poland with the same active substance: W Polsce znany jako
⚠ Not the same combination. This medicine contains Triamcinolone acetonide. The products below do not contain exactly the same set of active substances — they are not direct substitutes.
- Oridermyl partial — not the same combinationNeomycini sulfas, Nystatinum, Triamcinoloni acetonidum, Permethrinum · eye / ear / nose
- Recicort vet partial — not the same combinationTriamcinoloni acetonidum + Acidum salicylicum · eye / ear / nose
Some of these do not contain exactly the same active substances — check each one. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
💬 Ask about this leaflet
Ask anything about Nasacort 55 micrograms/dose, nasal spray, suspension. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.